CMV (Cytomegalovirus)

Biomarkers of Cytomegalovirus Fetal Infection and Disease

Condition:   Cytomegalovirus Congenital
Intervention:   Biological: Bio-specimen collected
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified March 2017

Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients

Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Valganciclovir;   Drug: Placebo
Sponsor:   Shire
Recruiting - verified April 2017

Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Investigator-Assigned Treatment
Sponsor:   Shire
Recruiting - verified February 2017

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Condition:   Cytomegalovirus Infections
Interventions:   Drug: VBI-1501A;   Drug: VBI-1501A;   Drug: VBI-1501A;   Drug: VBI-1501;   Drug: Placebo
Sponsors:   VBI Vaccines Inc.;   Clinical Trial Data Services, LLC;   Virginia Commonwealth University
Recruiting - verified July 2016

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Condition:   Cytomegalovirus Infection
Interventions:   Biological: Low dose HB-101;   Biological: Medium dose HB-101;   Biological: High dose HB-101;   Biological: Placebo
Sponsors:   Hookipa Biotech;   Centre for Vaccinology Ghent - CEVAC
Active, not recruiting - verified June 2016

Screening for Congenital Cytomegalovirus Infection in Newborns

Condition:   Cytomegalovirus Infections
Intervention:   Other: Observation
Sponsors:   Southern Illinois University;   University of Alabama at Birmingham
Enrolling by invitation - verified April 2017

Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence

Condition:   Cytomegalovirus Infections
Interventions:   Drug: Drug conversion to sirolimus;   Drug: Maintenance of the current regimen
Sponsor:   Hospital do Rim e Hipertensão
Recruiting - verified August 2016

The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University

Condition:   Cytomegalovirus Infections
Sponsor:   Jun Zhang
Completed - verified December 2015

Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine

Condition:   Congenital Cytomegalovirus Infection
Intervention:   Drug: CyMVectin
Sponsors:   Virginia Commonwealth University;   Vical
Withdrawn - verified September 2016

Cell-mediated Immunity for Prevention of CMV Disease

Condition:   Cytomegalovirus Infections
Intervention:   Other: T-Track® CMV assay
Sponsor:   University of Lausanne Hospitals
Recruiting - verified November 2016

A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China

Conditions:   Congenital Cytomegalovirus Infection;   Cytomegalovirus Infection Reactivation
Sponsors:   Jun Zhang;   Merck Sharp & Dohme Corp.;   National Natural Science Foundation of China
Recruiting - verified April 2017

SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients

Condition:   Cytomegalovirus Disease
Interventions:   Drug: Brincidofovir;   Drug: Valganciclovir
Sponsor:   Chimerix
Terminated - verified January 2017

Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

Condition:   Congenital Cytomegalovirus Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsor:   Rabin Medical Center
Recruiting - verified April 2017

MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

Condition:   Cytomegalovirus Infections
Interventions:   Drug: MK-8228;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified December 2016

Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive

Condition:   Cytomegalovirus Infections
Sponsors:   Fundacio Catalana de Pneumologia;   Roche Farma, S.A
Completed - verified September 2016

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Condition:   Cytomegalovirus Infections
Interventions:   Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Condition:   Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions:   Biological: ASP0113;   Drug: Placebo
Sponsors:   Astellas Pharma Global Development, Inc.;   Vical
Active, not recruiting - verified April 2017

Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero

Condition:   Congenital Cytomegalovirus Infection
Intervention:   Other: Standardized test report
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified December 2016

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients

Condition:   Cytomegalovirus Infections
Interventions:   Drug: MCMV3068A;   Drug: MCMV5322A;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed - verified March 2017

A Study in Adolescent Females to Explore Cytomegalovirus Infection

Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood collection;   Procedure: Urine collection;   Procedure: Saliva collection
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017

Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus

Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood sample;   Procedure: Cord blood sample;   Procedure: Saliva swab;   Procedure: Urine sampling;   Procedure: Vaginal swab
Sponsor:   GlaxoSmithKline
Completed - verified January 2017

Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients

Condition:   Cytomegalovirus
Intervention:   Biological: depistage
Sponsor:   University Hospital, Limoges
Completed - verified September 2016

Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

Condition:   Cytomegalovirus Infections
Intervention:   Biological: CMV-Peptide-Specific T cells
Sponsors:   Atara Biotherapeutics;   Memorial Sloan Kettering Cancer Center
Completed - verified February 2017

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Condition:   Cytomegalovirus Infections
Interventions:   Drug: Ganciclovir;   Drug: valganciclovir [Valcyte]
Sponsor:   Hoffmann-La Roche
Completed - verified November 2016

Cytomegalovirus (CMV) Infection in Pregnancy

Conditions:   Pregnancy Complications;   Cytomegalovirus Infection
Sponsor:   University of Pennsylvania
Completed - verified August 2016

Refine Your Search Advanced Search